2026-10-19T01:08:29Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/118732026-10-18T21:13:19Zopenairedrivercom_ebyu_10000col_ebyu_10001

Corrigendum to “What is the impact and efficacy of routine immunological, biochemical and hematological biomarkers as predictors of COVID-19 mortality?” [Int. Immunopharmacol. 105 (2022) 108542] (International Immunopharmacology (2022) 105, (S1567576922000261), (10.1016/j.intimp.2022.108542))Huyut, Mehmet TahirHuyut, ZübeyirIlkbahar, FatihMertoğlu, CumaerratumThe authors express their apologies for the minor errors mentioned below. First, the authors misidentified the significant p-values they show in Tables 1–8. Second, they miscalculated the 95% CI breakpoints of the PT value in Table 7. The authors report that the level of significance for p = 0.000 in Tables 1–8 is p < 0.001. They also state that the 95% CI values of the PT parameter specified in Table 7 are 1.63-2.56. These corrections do not affect the interpretation of the data or the conclusions drawn. The authors apologize to the journal and readers for these unintentional errors. © 2023 Elsevier B.V.Elsevier B.V.2023Correctionhttps://rdlopen.rawdatalibrary.net/r/ebyu/11873https://doi.org/10.1016/j.intimp.2023.1108211567-5769enInternational Immunopharmacologyinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/11873